Q3 EPS Forecast for Indaptus Therapeutics Reduced by Analyst

Indaptus Therapeutics, Inc. (NASDAQ:INDP) – Research analysts at HC Wainwright dropped their Q3 2024 earnings per share estimates for Indaptus Therapeutics in a report issued on Wednesday, October 16th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.47) for the quarter, down from their prior estimate of ($0.42). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.72) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q4 2024 earnings at ($0.41) EPS, FY2024 earnings at ($1.79) EPS, Q1 2025 earnings at ($0.41) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.32) EPS and FY2025 earnings at ($1.38) EPS.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07.

Indaptus Therapeutics Stock Up 29.8 %

Shares of INDP stock opened at $1.91 on Monday. The firm has a 50 day moving average price of $1.43 and a two-hundred day moving average price of $1.97. The company has a market capitalization of $16.29 million, a PE ratio of -1.07 and a beta of 1.46. Indaptus Therapeutics has a 12-month low of $1.03 and a 12-month high of $3.25.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned about 0.17% of Indaptus Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.